Effects of hemolysis and lipemia on the COBAS® salicylate and acetaminophen assays compared to GDS assays

Danni Meany; Jeffery Schowinsky; William Clarke

doi:10.1016/j.clinbiochem.2008.09.111

Effects of hemolysis and lipemia on the COBAS® salicylate and acetaminophen assays compared to GDS assays

Danni Meany, Jeffery Schowinsky, William Clarke

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Objective: We compared the COBAS® acetaminophen and salicylate assays (Roche Diagnostics) with the Stanbio GDS assays (Stanbio Laboratories) that are currently used in our laboratory with respect to interferences from hemolysis and lipemia. Methods: Acetaminophen and salicylate were added into human serum with varying concentrations of hemoglobin or Intralipid® to generate a range of acetaminophen and salicylate concentrations. Then the COBAS® and GDS assays were used to measure the apparent drug concentrations; the H and L indices were measured to determine the extent of hemolysis and lipemia present in each specimen. Results: Both hemolysis and lipemia have less effect on the COBAS® acetaminophen and salicylate assays than on the GDS assays. Conclusions: The COBAS® assays for acetaminophen and salicylate are preferable to the current GDS assays in clinical toxicology laboratories.

Original language	English (US)
Pages (from-to)	1486-1488
Number of pages	3
Journal	Clinical Biochemistry
Volume	41
Issue number	18
DOIs	https://doi.org/10.1016/j.clinbiochem.2008.09.111
State	Published - Dec 1 2008
Externally published	Yes

Keywords

Acetaminophen
Hemolysis
Interference
Lipemia
Salicylate

Access

10.1016/j.clinbiochem.2008.09.111

OpenUrl availability

Full text

Cite this

@article{1144c4480ff94e9d84c5d0cd92875004,

title = "Effects of hemolysis and lipemia on the COBAS{\textregistered} salicylate and acetaminophen assays compared to GDS assays",

abstract = "Objective: We compared the COBAS{\textregistered} acetaminophen and salicylate assays (Roche Diagnostics) with the Stanbio GDS assays (Stanbio Laboratories) that are currently used in our laboratory with respect to interferences from hemolysis and lipemia. Methods: Acetaminophen and salicylate were added into human serum with varying concentrations of hemoglobin or Intralipid{\textregistered} to generate a range of acetaminophen and salicylate concentrations. Then the COBAS{\textregistered} and GDS assays were used to measure the apparent drug concentrations; the H and L indices were measured to determine the extent of hemolysis and lipemia present in each specimen. Results: Both hemolysis and lipemia have less effect on the COBAS{\textregistered} acetaminophen and salicylate assays than on the GDS assays. Conclusions: The COBAS{\textregistered} assays for acetaminophen and salicylate are preferable to the current GDS assays in clinical toxicology laboratories.",

keywords = "Acetaminophen, Hemolysis, Interference, Lipemia, Salicylate",

author = "Danni Meany and Jeffery Schowinsky and William Clarke",

year = "2008",

month = dec,

day = "1",

doi = "10.1016/j.clinbiochem.2008.09.111",

language = "English (US)",

volume = "41",

pages = "1486--1488",

journal = "Clinical Biochemistry",

issn = "0009-9120",

publisher = "Elsevier Inc.",

number = "18",

}

TY - JOUR

T1 - Effects of hemolysis and lipemia on the COBAS® salicylate and acetaminophen assays compared to GDS assays

AU - Meany, Danni

AU - Schowinsky, Jeffery

AU - Clarke, William

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Objective: We compared the COBAS® acetaminophen and salicylate assays (Roche Diagnostics) with the Stanbio GDS assays (Stanbio Laboratories) that are currently used in our laboratory with respect to interferences from hemolysis and lipemia. Methods: Acetaminophen and salicylate were added into human serum with varying concentrations of hemoglobin or Intralipid® to generate a range of acetaminophen and salicylate concentrations. Then the COBAS® and GDS assays were used to measure the apparent drug concentrations; the H and L indices were measured to determine the extent of hemolysis and lipemia present in each specimen. Results: Both hemolysis and lipemia have less effect on the COBAS® acetaminophen and salicylate assays than on the GDS assays. Conclusions: The COBAS® assays for acetaminophen and salicylate are preferable to the current GDS assays in clinical toxicology laboratories.

AB - Objective: We compared the COBAS® acetaminophen and salicylate assays (Roche Diagnostics) with the Stanbio GDS assays (Stanbio Laboratories) that are currently used in our laboratory with respect to interferences from hemolysis and lipemia. Methods: Acetaminophen and salicylate were added into human serum with varying concentrations of hemoglobin or Intralipid® to generate a range of acetaminophen and salicylate concentrations. Then the COBAS® and GDS assays were used to measure the apparent drug concentrations; the H and L indices were measured to determine the extent of hemolysis and lipemia present in each specimen. Results: Both hemolysis and lipemia have less effect on the COBAS® acetaminophen and salicylate assays than on the GDS assays. Conclusions: The COBAS® assays for acetaminophen and salicylate are preferable to the current GDS assays in clinical toxicology laboratories.

KW - Acetaminophen

KW - Hemolysis

KW - Interference

KW - Lipemia

KW - Salicylate

UR - http://www.scopus.com/inward/record.url?scp=55949089038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949089038&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2008.09.111

DO - 10.1016/j.clinbiochem.2008.09.111

M3 - Article

C2 - 18950612

AN - SCOPUS:55949089038

SN - 0009-9120

VL - 41

SP - 1486

EP - 1488

JO - Clinical Biochemistry

JF - Clinical Biochemistry

IS - 18

ER -

Effects of hemolysis and lipemia on the COBAS® salicylate and acetaminophen assays compared to GDS assays

Abstract

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this